NCT02350686

XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

Phase II Study of Second Line Capecitabine Plus Oxaliplatin (XELOX) in Patients With Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 67 (estimated)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase II study of second line capecitabine plus oxaliplatin (XELOX) in patients with advanced biliary tract carcinoma after failure of gemcitabine-based chemotherapy.

Detailed description

XELOX * Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks * Oxaliplatin 130mg/㎡, day 1, every 3 weeks Until disease progression, patient's refusal or up to 8 cycles (maximum).

Conditions

• Biliary Tract Cancer

Interventions

Type	Name	Description
DRUG	capecitabine	XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
DRUG	oxaliplatin	XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles

Timeline

• Start date: 2015-05-14
• Primary completion: 2019-12-01
• Completion: 2020-12-01
• First posted: 2015-01-30
• Last updated: 2019-05-20

Locations

1 site across 1 country: South Korea